Cartesian Therapeutics, Inc.RNACNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -94.09% | -109.18% | -81.16% | -99.11% | +16.80% |
| Gross Profit Growth | +0.00% | -109.18% | -81.16% | -99.11% | -3289.92% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +18.07% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | -258.54% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +14.82% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +5.17% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +11.11% | +0.00% |
| Weighted Average Shares Growth | +316.10% | +401.07% | +378.44% | +55.35% | +21.10% |
| Weighted Average Shares Diluted Growth | +316.10% | +401.07% | +378.44% | +48.65% | +21.10% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -213.94% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -325.47% |
| Receivables Growth | -14.23% | -90.15% | -59.67% | -99.00% | -87.57% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +329.41% | +42.61% | +25.81% | +11.84% | -18.15% |
| Book Value per Share Growth | -99.70% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +39.79% | +27.65% | +34.51% | -10.21% | -13.98% |
| R&D Expense Growth | -12.32% | -49.60% | +50.69% | +17.44% | +21.07% |
| SG&A Expenses Growth | -0.79% | -68.03% | -12.01% | +3.03% | +17.59% |